Carfilnat is a prescription medication used to treat multiple myeloma, a type of blood cancer. It is an injectable drug that contains the active ingredient carfilzomib, which belongs to a class of drugs called proteasome inhibitors.
Carfilnat contains the active ingredient carfilzomib. Each vial of Carfilnat contains 60 mg of carfilzomib in 2 mL of solution for injection.
Carfilnat is used to treat multiple myeloma in patients who have received at least one prior therapy. It is used in combination with other medications to slow or stop the growth of cancer cells and improve symptoms of the disease.
How to use Carfilnat:
Carfilnat is administered through intravenous (IV) infusion by a healthcare professional. The injection is given slowly over a period of 10 minutes. The typical recommended dose of Carfilnat is 20 mg/m2, given on days 1 and 2 of a 28-day treatment cycle. Your doctor will determine the appropriate dose and duration of treatment for you.
The recommended dose of Carfilnat is based on patient weight and height. The dose is typically given on days 1 and 2 of a 28-day treatment cycle. Your doctor will determine the appropriate dose and duration of treatment for you.
Carfilnat should be stored in a refrigerator between 2°C to 8°C. Do not freeze or shake the vial. Keep it out of reach of children and pets.
Mechanism of Action:
Carfilzomib works by inhibiting the activity of proteasomes, which are enzymes that break down proteins in the body. Proteasomes play a key role in the growth and survival of cancer cells. By inhibiting proteasomes, carfilzomib can slow or stop the growth of cancer cells and induce cell death.
Carfilnat should not be used in patients who are allergic to carfilzomib or any other components of the drug. It may cause serious side effects in patients with heart, liver, or kidney problems. Carfilnat may cause fetal harm if used during pregnancy. It is important to use effective birth control while receiving treatment with Carfilnat.
Carfilnat is contraindicated for patients with severe allergic reactions to carfilzomib. It should not be used in combination with certain medications, such as strong CYP3A inducers or inhibitors. It should also be avoided in patients with severe liver or kidney disease.
Carfilnat may interact with other medications, especially those that affect liver enzymes, such as rifampin, carbamazepine, and phenytoin. Always inform your doctor of any medications you are taking before starting treatment with Carfilnat.
In the event of an overdose, contact your doctor or seek emergency medical attention immediately. Symptoms of overdose may include low blood pressure, shortness of breath, and heart problems.
Common side effects of Carfilnat include fatigue, nausea, diarrhea, and low blood cell counts. Serious side effects may include heart problems, infusion-related reactions, and lung damage. If you experience any unusual symptoms while taking Carfilnat, seek medical attention immediately.